What is HC Wainwright’s Forecast for JANX Q1 Earnings?

Janux Therapeutics, Inc. (NASDAQ:JANX) – Research analysts at HC Wainwright issued their Q1 2027 earnings estimates for shares of Janux Therapeutics in a note issued to investors on Monday, May 11th. HC Wainwright analyst S. Ramakanth forecasts that the company will post earnings of ($0.56) per share for the quarter. The consensus estimate for Janux Therapeutics’ current full-year earnings is ($2.33) per share. HC Wainwright also issued estimates for Janux Therapeutics’ Q2 2027 earnings at ($0.59) EPS, Q3 2027 earnings at ($0.63) EPS, Q4 2027 earnings at ($0.66) EPS and FY2030 earnings at $1.06 EPS.

A number of other analysts have also commented on JANX. Truist Financial raised shares of Janux Therapeutics to a “strong-buy” rating in a report on Monday, May 4th. Wedbush reduced their price target on shares of Janux Therapeutics from $45.00 to $36.00 and set an “outperform” rating on the stock in a research report on Friday. Clear Str cut shares of Janux Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 20th. Evercore set a $22.00 price target on shares of Janux Therapeutics in a research report on Monday. Finally, Guggenheim reduced their price target on shares of Janux Therapeutics from $68.00 to $58.00 and set a “buy” rating on the stock in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Janux Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $45.85.

Janux Therapeutics Stock Performance

JANX opened at $14.23 on Tuesday. The company has a fifty day moving average price of $14.37 and a two-hundred day moving average price of $17.27. Janux Therapeutics has a 52 week low of $12.12 and a 52 week high of $35.34. The firm has a market capitalization of $867.75 million, a PE ratio of -7.73 and a beta of 2.58.

Janux Therapeutics (NASDAQ:JANX) last released its earnings results on Thursday, May 7th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.13. The business had revenue of $3.73 million for the quarter, compared to analyst estimates of $4.36 million.

Institutional Investors Weigh In On Janux Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. California State Teachers Retirement System lifted its position in Janux Therapeutics by 1.1% in the 2nd quarter. California State Teachers Retirement System now owns 37,139 shares of the company’s stock valued at $858,000 after acquiring an additional 404 shares in the last quarter. Nuveen LLC lifted its position in Janux Therapeutics by 0.8% in the 4th quarter. Nuveen LLC now owns 96,416 shares of the company’s stock valued at $1,331,000 after acquiring an additional 787 shares in the last quarter. Congress Asset Management Co. lifted its position in Janux Therapeutics by 2.8% in the 4th quarter. Congress Asset Management Co. now owns 57,342 shares of the company’s stock valued at $791,000 after acquiring an additional 1,569 shares in the last quarter. ProShare Advisors LLC lifted its position in Janux Therapeutics by 18.3% in the 4th quarter. ProShare Advisors LLC now owns 10,495 shares of the company’s stock valued at $145,000 after acquiring an additional 1,621 shares in the last quarter. Finally, Kennedy Capital Management LLC lifted its position in Janux Therapeutics by 20.0% in the 3rd quarter. Kennedy Capital Management LLC now owns 11,413 shares of the company’s stock valued at $279,000 after acquiring an additional 1,905 shares in the last quarter. 75.39% of the stock is owned by institutional investors.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.